Posted by Jessica Moore on Apr 25th, 2024
GeneDx (NASDAQ:WGS – Free Report) had its price objective lifted by BTIG Research from $11.00 to $15.00 in a research report report published on Monday, Benzinga reports. BTIG Research currently has a buy rating on the stock.
Separately,...
More of this article »